Jennifer Lachey, Chief Scientific Officer at Keros Therapeutics, Inc. (KROS), sold 7,950 shares at $60.00 ($477K) on 2022-04-04, disclosed to the SEC on 2022-04-06.
Open-market sale of $477k KROS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| KROS | SELL | 2022-05-13 | $362K | — | Filing → |
| KROS | SELL | 2022-04-13 | $630K | — | Filing → |
| KROS | SELL | 2022-03-15 | $197K | — | Filing → |